Nippon India Pharma Fund - Direct Plan - Growth Plan
Equity
Direct
Sector - Healthcare
NAV: ₹ 322.8 as on 02-06-2023
Fund Performance
5935 people have invested ₹ 1.3Cr in Nippon India Pharma Fund - Direct Plan - Growth Plan in the last three months
Fund Insights
In the last 1 year, SBI Healthcare Opportunities Fund Direct Growth has given 17.88% return, outperforming Nippon India Pharma Fund - Direct Plan - Growth Plan by 5.66%
In the last 3 years, DSP Healthcare Fund Direct Growth has given 21.55% return, outperforming Nippon India Pharma Fund - Direct Plan - Growth Plan by 4.09% per annum
In the last 5 years, Mirae Asset Healthcare Fund Direct Growth has given 18.52% return, outperforming Nippon India Pharma Fund - Direct Plan - Growth Plan by 0.44% per annum
Over the last 1 month, Nippon India Pharma Fund - Direct Plan - Growth Plan has decreased expense ratio by 16.7% moving from 1.26 to 1.05
Nippon India Pharma Fund - Direct Plan - Growth Plan has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.05% which is lower than the category average expense ratio of 1.54%
Nippon India Pharma Fund - Direct Plan - Growth Plan with AUM at ₹4510.77Cr is among the largest funds in the sector - healthcare category
Over the last 6 months, Nippon India Pharma Fund - Direct Plan - Growth Plan has experienced a 5.7% drop in AUM moving from 4.78K Cr to 4.51K Cr
INDmoney Rank
Powered by IND quant engine
IND ranking is not available for this fund.
Pros
5Y returns in the top 25% of the category
3Y returns in the top 25% of the category
Among most bought funds within the category
Cons
No bad points found for this fund.
About the Fund
Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Akshay Sharma, Kinjal Desai. The fund could potentially beat inflation in the long-run.
Key Parameters
- Nippon India Pharma Fund - Direct Plan - Growth Plan has a NAV of ₹322.8 as on 02-06-2023.
- Nippon India Pharma Fund - Direct Plan - Growth Plan has ₹4511 Cr worth of assets under management (AUM) as on 30-04-2023 and is more than category average.
- The fund has an expense ratio 1.1.
Nippon India Pharma Fund - Direct Plan - Growth Plan Overview
 | 1.05% |
 Benchmark | S&P BSE Healthcare PR |
 | ₹4511 Cr |
 | 1 January, 2013 |
 | ₹5000/₹100 |
 Exit Load | 1% |
 | No Lock-in |
 TurnOver | 38.42% |
Fund Distribution as on (30-Apr-23)
Size breakup
Large cap
41.5%
Mid cap
32.3%
Small cap
22.6%
Sector Allocation
Health
100%
Top Holdings of Nippon India Pharma Fund - Direct Plan - Growth Plan as on (31-May-23)
Equity Holdings28
Nippon India Pharma Fund - Direct Plan - Growth Plan: Monthly Changes Updates
All changes are between Feb'23 and Apr'23
Fund Performance
- This fund’s returns stands at 1.51% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.73% as on Apr'23
- This fund outperformed Nifty 500 by 2.24% in Apr'23
AUM Change
- AUM of the fund stands at 4.5K Cr as of Apr'23
- AUM increased by 206.3 Cr between Apr'23 and Mar'23
Fund Portfolio Changes
Gainers & Losers in Nippon India Pharma Fund - Direct Plan - Growth Plan portfolio as on (30-Apr-23)
Top Growth Drivers | 1M Return |
|---|---|
 Aurobindo Pharma Ltd | 18.6% |
 Divis Laboratories Ltd | 13.7% |
 Lupin Ltd | 8.9% |
Peer Analysis
Nippon India Pharma Fund - Direct Plan - Growth Plan Fund Manager
Sailesh Raj Bhan
Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 1 April 2005
Top funds managed
Akshay Sharma
Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 1 December 2022
Top funds managed
Kinjal Desai
Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 25 May 2018
Top funds managed
Fund Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 15.85% since inception which is more than its category average return of 15.5%
Fund Allocations
This fund has an allocation of 96.77% in Equity, 0% in Debt and 3.23% in Cash related instruments
AUM size ₹4511 Cr
This fund has AUM of ₹4511 Cr which is more than its category average of ₹ 1299 Cr
Expense Ratio 1.05%
This fund has an expense ratio of 1.05% which is less than its category average expense ratio of 1.52%
Frequently Asked Questions
The current NAV of Nippon India Pharma Fund - Direct Plan - Growth Plan is ₹322.81 as on 02-Jun-2023.
Existing (Absolute + CAGR) as on 02-Jun-2023.
Nippon India Pharma Fund - Direct Plan - Growth Plan | Absolute Returns | CAGR Returns |
1 Month Returns | 4.65% | 4.65% |
6 Month Returns | 1.63% | 1.63% |
1 Year Returns | 12.22% | 12.22% |
3 Years Returns | 62.07% | 17.46% |
5 Years Returns | 129.55% | 18.08% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.05% as on May 2023
₹4511 Cr as on May 2023
Sun Pharmaceuticals Industries Ltd(14.36%), Dr Reddy's Laboratories Ltd(7.1%), Lupin Ltd(6.93%), Cipla Ltd Shs Dematerialised(6.04%), Apollo Hospitals Enterprise Ltd(5.21%) as on May 2023
The alpha ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 2.89 | 1.87 | 4.22 |
As on May 2023
The alpha for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 0.87 | 0.93 | 0.89 |
As on May 2023
The Beta for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 0.33 | 0.81 | 0.7 |
As on May 2023
The sharpe ratio for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 10.4 | 15.3 | 18.15 |
As on May 2023
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.46 as on May 2023. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.42 as on May 2023. It tells the consistency of the fund in generating superior risk-adjusted performance
Sailesh Raj Bhan, Akshay Sharma, Kinjal Desai are the fund managers of Nippon India Pharma Fund - Direct Plan - Growth Plan
The Exit load of Nippon India Pharma Fund - Direct Plan - Growth Plan is 1%